We use cookies and similar technologies to help our website function, understand how visitors use our site, and improve your experience. Some cookies are necessary for the website to operate, while others may be used for analytics or advertising.
Viewing as a visitor in
Legal News, Information & Blogs
Judge Upholds FDA Deadline Ending Production of Compounded Ozempic and Wegovy
A U.S. federal judge ruled on Thursday against compounding pharmacies seeking permission to continue producing copies of Novo Nordisk's widely popular diabetes and weight-loss drugs, Ozempic and Wegovy, while a legal battle over drug shortages continues.
Judge Mark Pittman of the U.S. District Court in Texas rejected a request from compounders for a preliminary injunctionA preliminary injunction is a temporary court order issued before a case is finally decided that requires a party to take or stop an action while the litigation continues. Federal courts generally consider the likelihood of success, irreparable harm, the balance of equities, and the public interest before granting one.Read more →, effectively upholding a May 22 deadline set by the U.S. Food and Drug Administration (FDA). From this date forward, large-scale compounders must stop producing the drugs. Smaller pharmacies, regulated primarily by state authorities and producing tailored prescriptions for individual patients, must immediately cease production.
Compounding pharmacies, often simply called compounders, are facilities that create customized medications by mixing, altering, or combining pharmaceutical ingredients. Compounders typically step in to produce medications when commercial drugs face shortages or when specific formulations are required to meet individual patient needs, such as unique dosages, allergy accommodations, or different delivery methods. Their role has become particularly critical during supply shortages of popular medications, providing alternatives when brand-name drugs are unavailable or insufficiently stocked.
The lawsuit originated from a February challenge filed by the Outsourcing Facilities Association, representing compounding pharmacies. The group contested the FDA's determination that the active ingredient in both drugs, semaglutide, was no longer in shortage. During shortages, compounders typically have the legal flexibility to produce replicas of brand-name medications by mixing or altering ingredients.
Compounders had produced hundreds of thousands of doses of Ozempic and Wegovy equivalents during the previously declared shortage period. These compounded medications have been widely sold by telehealth platforms, notably including Hims & Hers.
While Judge Pittman's detailed reasoning remains under seal, the denial mirrors his earlier decision involving compounding pharmacies' attempts to continue making generic copies of Eli Lilly's weight-loss drugs, Zepbound and Mounjaro.
Lee Rosebush, chairman of the Outsourcing Facilities Association, expressed disappointment to Reuters in the ruling, emphasizing that recent evidence, not considered by the judge, showed ongoing shortages of semaglutide. "We believe the data shows that there is still a shortage of these products," Rosebush stated.
Conversely, Novo Nordisk applauded the decision. "We are pleased the court rejected compounders' attempts to undermine FDA’s data-based decision," said Steve Benz, general counsel at Novo Nordisk. The pharmaceutical giant has actively litigated against unauthorized sellers of compounded semaglutide, filing 111 lawsuits across 32 states to date.
Novo Nordisk continues to dominate the market with these medications. Analysts forecast that Ozempic and Wegovy will generate approximately $20.1 billion and $14.79 billion, respectively, in global revenue for the company this year.
The FDA previously indicated it would refrain from enforcement actions against compounders until the court issued its ruling.
Share This Article
If you found this article insightful, consider sharing it with your network.
Lawrence is an attorney and CEO of Law Commentary. Lawrence draws on his legal and business experience to help make court decisions, litigation, legislation, public policy, and other legal developments more accessible to the general public and to give readers clear context for understanding the law and how it affects businesses, consumers, and communities.
A Washington state judge ordered Albertsons and its Safeway subsidiary to pay $900 million on Thursday, November 5, 2026, after finding that their pharmacies repeatedly failed to properly investigate suspicious opioid prescriptions and substantially contributed to the state’s overdose crisis.King County Superior Court Judge Janet Helson found that Albertsons violated...
Read
More about Albertsons, Safeway Ordered to Pay $900 Million Over Washington Opioid Crisis »
The pharmaceutical industry’s leading trade group is suing the Trump administration over a new Medicare drug-pricing program that could lower out-of-pocket costs for some patients receiving expensive cancer, autoimmune, and other medications administered in medical settings.The Pharmaceutical Research and Manufacturers of America, or PhRMA, filed the lawsuit on October 7,...
Read
More about Drugmakers Sue to Block Trump Medicare Plan Tying Drug Costs to Lower Foreign Prices »
Three UnitedHealth Group subsidiaries must remain defendants in federal lawsuits accusing Optum and other companies tied to pharmacy benefit management of contributing to the opioid epidemic, after an Ohio judge rejected their latest effort to leave the cases.U.S. District Judge Dan Aaron Polster ruled October 15 that OptumHealth Care Solutions...
Read
More about UnitedHealth’s OptumHealth Must Remain in Opioid Lawsuits, Judge Rules »
Novo Nordisk must face part of a securities fraud lawsuit accusing the drugmaker of misleading investors about dosing and tolerability in a late-stage clinical trial for CagriSema, after a federal judge allowed a narrower set of shareholder claims to move forward.U.S. District Judge Robert Kirsch in New Jersey ruled Tuesday...
Read
More about Novo Nordisk Must Face Investor Fraud Claims Over CagriSema Trial Disclosures »